Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Adma Biologics (ADMA) Interest Expenses (2016 - 2025)

Adma Biologics (ADMA) has disclosed Interest Expenses for 13 consecutive years, with $1.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Interest Expenses fell 43.52% year-over-year to $1.6 million, compared with a TTM value of $7.1 million through Dec 2025, down 48.96%, and an annual FY2025 reading of $7.1 million, down 48.96% over the prior year.
  • Interest Expenses was $1.6 million for Q4 2025 at Adma Biologics, down from $1.7 million in the prior quarter.
  • Across five years, Interest Expenses topped out at $6.4 million in Q3 2023 and bottomed at $1.6 million in Q4 2025.
  • Average Interest Expenses over 5 years is $3.9 million, with a median of $3.4 million recorded in 2022.
  • The sharpest move saw Interest Expenses soared 80.43% in 2023, then tumbled 53.68% in 2024.
  • Year by year, Interest Expenses stood at $3.3 million in 2021, then soared by 73.0% to $5.7 million in 2022, then increased by 8.34% to $6.2 million in 2023, then crashed by 53.68% to $2.9 million in 2024, then tumbled by 43.52% to $1.6 million in 2025.
  • Business Quant data shows Interest Expenses for ADMA at $1.6 million in Q4 2025, $1.7 million in Q3 2025, and $1.8 million in Q2 2025.